Dilantin and Skin disorder - a phase IV clinical study of FDA data

Summary:

Skin disorder is reported as a side effect among people who take Dilantin (phenytoin sodium), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Lipitor, and have Convulsion.

The phase IV clinical study analyzes which people have Skin disorder when taking Dilantin. It is created by eHealthMe based on reports of 19,857 people who have side effects when taking Dilantin from the FDA, and is updated regularly.

What is Dilantin?

Dilantin has active ingredients of phenytoin sodium. It is often used in epilepsy. eHealthMe is studying from 20,858 Dilantin users. Check the latest studies of Dilantin.

What is Skin disorder?

Skin disorder (skin disease) is found to be associated with 1,545 drugs and 1,448 conditions by eHealthMe. Check the latest studies of Skin disorder.

On Jul, 12, 2026

19,857 people reported to have side effects when taking Dilantin.
Among them, 56 people (0.28%) have Skin disorder.

Among these 56 people:

How long have people been on Dilantin when they have Skin disorder? *

What is the gender of people who have Skin disorder when taking Dilantin? *

female: 53.7 %
male: 46.3 %

What is the age of people who have Skin disorder when taking Dilantin? *

What are other drugs people take besides Dilantin? *

What are other side effects people have besides Skin disorder? *

Rashes (redness): 15 people, 26.79%
Pain: 14 people, 25.00%
Itching: 14 people, 25.00%
Fatigue (feeling of tiredness): 13 people, 23.21%
Weakness: 11 people, 19.64%
Feeling Abnormal: 9 people, 16.07%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 9 people, 16.07%
Gait Disturbance: 8 people, 14.29%
Fever: 8 people, 14.29%
Joint Pain: 8 people, 14.29%

What are the existing conditions these people have? *

Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 16 people, 28.57%
Nuclear Magnetic Resonance Imaging Brain: 6 people, 10.71%
Nuclear Magnetic Resonance Imaging Abdominal: 4 people, 7.14%
Cardiac Disorder: 3 people, 5.36%
Osteoporosis (bones weak and more likely to break): 3 people, 5.36%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 5.36%
Stress And Anxiety: 3 people, 5.36%
High Blood Pressure: 2 people, 3.57%
Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 2 people, 3.57%
High Blood Cholesterol: 2 people, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Dilantin and have Skin disorder?

- Check whether Skin disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dilantin:

Dilantin (20,858 reports)

Skin disorder treatments and more:

Skin disorder (41,532 reports)

Browse all side effects of Dilantin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin disorder:

Skin disorder (1,545 drugs)

Browse all the conditions that are associated with Skin disorder:

Skin disorder (1,448 conditions)

Related publications that referenced our studies

Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Moftah NH, Kamel AM, Attia HM, El-Baz MZ, El–Moty HM, "Skin diseases in patients with primary psychiatric conditions: a hospital based study", Journal of epidemiology and global health, 2013 Sep .
Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Moftah NH, Kamel AM, Attia HM, El-Baz MZ, El–Moty HM, "Skin diseases in patients with primary psychiatric conditions: a hospital based study", Journal of epidemiology and global health, 2013 Sep .

How the study uses the data?

The study uses data from the FDA. It is based on phenytoin sodium (the active ingredients of Dilantin) and Dilantin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.